Utility of gene panel testing for comprehensive genomic profiling of blood cancers demonstrated- prospects for genomic medicine for blood cancers -
July 1, 2022
National Cancer Center Japan
- A gene panel testing to detect recurrent genetic alterations in blood cancer patients was developed and evaluated.
- A prospective cohort study demonstrated the clinical utility of panel testing in diagnosis, prognosis, and treatment decisions. It was notably high in diagnosis and prognosis.
- This is the first study reporting the efficacy of blood cancer gene panel testing in Japan, which is expected to contribute to the spread of comprehensive genomic profiling and provide a basis for genome medicine for blood cancers.
The National Cancer Center conducted a prospective cohort study on the gene panel testing for blood cancers (hematological malignancies) developed with Otsuka Pharmaceutical Co., Ltd in 2020 for diagnosis, treatment decisions, and prognosis. This study included samples from 176 patients with blood cancers. The results demonstrated the clinical utility of comprehensive genome profiling in blood cancers, which is expected to contribute to the spread of comprehensive genomic profiling and provide a basis for genome medicine for blood cancers.
This result was reported in the June 17 edition of Cancer Science.
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Suguru Fukuhara, Yuji Oshikawa-Kumade, Yasunori Kogure,Sumito Shingaki,
Hirokazu Kariyazono, Yoshiya Kikukawa, Junji Koya, Yuki Saito, Mariko Tabata, Kota Yoshifuji,
Kota Mizuno, Akiko,Miyagi-Maeshima, Hiromichi Matsushita, Masanaka Sugiyama,
Chitose Ogawa, Yoshihiro Inamoto, Takahiro Fukuda, Masato Sugano, Nobuhiko Yamauchi,
Yosuke Minami, Makoto Hirata, Teruhiko Yoshida, Takashi Kohno, Shinji Kohsaka,
Hiroyuki Mano,Yuichi Shiraishi, Seishi Ogawa, Koji Izutsu, Keisuke Kataoka
https://doi.org/10.1111/cas.15427(link to external site)
June 17, 2022
This project was supported in part by the National Cancer Center Research and Development Fund, and by Otsuka Pharmaceutical Co., Ltd.